Targeting survivin in cancer

With almost 4000 citations in Medline in a little over 10years, survivin has certainly kept scores of investigators busy worldwide. Tangible progress has been made in revealing the multiple functions of survivin, uncovering their wirings as integrated cellular networks, and mapping their exploitatio...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2013-05, Vol.332 (2), p.225-228
Main Author: Altieri, Dario C
Format: Article
Language:English
Subjects:
Animals
antagonists
Antisense
Apoptosis
Cancer
Cancer therapy
Cell cycle
Chemistry, Pharmaceutical - methods
clinical trials
Clinical Trials as Topic
Drug Delivery Systems
Drug Design
drugs
Gene expression
Gene Expression Regulation, Neoplastic
Hematology, Oncology and Palliative Medicine
Humans
IAP
Immunotherapy - methods
Inhibitor of Apoptosis Proteins - metabolism
Kinases
Microtubule-Associated Proteins - metabolism
Neoplasm Proteins - metabolism
Neoplasms - metabolism
Neoplasms - pathology
Oligonucleotides, Antisense - pharmacology
patients
pressing
Proteins
Signal Transduction
Signaling networks
Small molecule
Stress response
Studies
Survivin
therapeutics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:With almost 4000 citations in Medline in a little over 10years, survivin has certainly kept scores of investigators busy worldwide. Tangible progress has been made in revealing the multiple functions of survivin, uncovering their wirings as integrated cellular networks, and mapping their exploitation in virtually every human tumor, in vivo. Considering the normally long and excruciating timeline of oncology drug discovery, it is clearly a resounding success that a better understanding of survivin biology has led to several clinical trials of survivin-based therapeutics in cancer patients. However, the portfolio of survivin antagonists available in the clinic remains small, pressing the need for a less rigid drug development approach to fully unlock the potential of this unique, albeit unconventional oncology drug target.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2012.03.005